Maria LOUSTAU

Dr. Maria Loustau holds a PhD in Biotechnology, with expertise in Biochemistry, Biotechnology and Immunology. She joined the leading HLA-G research team in Paris (2010) to work on HLA-G expression patterns and HLA-G recombinant expression and purification. She joined Invectys in 2011 and since she has been leading projects related to the human health Immunotherapies’ field development, notably on HLA-G immunotherapies research by first developing new methods to induce anti-HLA-G antibodies (2012). Later, she made several new achievements by isolating the first-in-class blocking antibodies and nanobodies against the HLA-G/ILT4 immune checkpoint pair (2016, 2019), developing the first immunotherapy targeting HLA-G through the generation of anti-HLA-G CAR-T cells (2018), and contributing to iNKT cells therapeutic adjuvant project (2021). She is co-inventor of 6 patents related to HLA-G and immunotherapeutic products. Currently, she is involved in translational partnerships management with laboratories of hospitals, academia and industry.